Plain-English translation of NCT05597306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination of two medications— and —to treat acute myeloid leukemia (AML) that has returned or stopped responding to standard treatment. Researchers want to find out if these two drugs work well together and are safe when given to patients. The study will also determine the best dose for this combination.
Many patients with AML find that standard treatments stop working over time, leaving them with few options. This medication combination is designed to attack the cancer in a new way, and this trial will help doctors understand whether it can help patients whose cancer is resistant to older treatments.
You likely qualify if…
You likely don't qualify if…
You will take both medications by mouth for 21 days followed by 7 days off, repeating this cycle every 28 days for at least 3 months. The study will start you at a certain dose and may adjust it based on how well you tolerate the treatment. You will have regular blood tests and clinic visits to check your safety and how you're responding to the medications.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Terrence J Bradley, MD
Collaborators
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Enrollment target
~18 participants
Started
November 2022
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alessia Zoso, PhD
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.